Agios Pharmaceuticals (AGIO) Current Assets (2012 - 2026)

Agios Pharmaceuticals has reported Current Assets for 15 years, with the latest figure at $834.8 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 13.81% year-over-year to $834.8 million; the trailing twelve-month figure through Mar 2026 stood at $834.8 million (down 13.81% YoY), and the FY2025 full-year result was $942.1 million, down 2.44% from the prior year.
• Current Assets for Q1 2026 stood at $834.8 million, down from $942.1 million in the prior quarter.
• The five-year high for Current Assets was $1.1 billion in Q3 2024, with the low at $632.1 million in Q2 2024.
• Historically, Current Assets has averaged $863.7 million across 5 years, with a median of $834.8 million in 2026.
• Annual changes were most pronounced in 2022 — Current Assets tumbled 58.59% — and 2025, when it soared 61.28%.
• Agios Pharmaceuticals' Current Assets stood at $832.8 million in 2022, then gained by 0.13% to $833.8 million in 2023, then climbed by 15.8% to $965.6 million in 2024, then declined by 2.44% to $942.1 million in 2025, then declined by 11.38% to $834.8 million in 2026.
• The last three Current Assets figures came in at $834.8 million (Q1 2026), $942.1 million (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.